PARTNERING WITH HEOR EXPERTS
Academic Partners
Health Analytics partners with academia to ensure that our services remain innovative. Our strategic academic partnerships enable us to draw on the very latest science of our field and apply what we learn for the benefit of our clients.
Martha Sajatovic, M.D.
University Hospitals Cleveland Medical Center (UHCMC)
- Willard Brown Chair in Neurological Outcomes at University Hospitals Cleveland Medical Center (UHCMC)
- Directs the Neurological and Behavioral Outcomes Center at UHCMC/Case Western Reserve University
Martha Sajatovic, MD is the Willard Brown Chair in Neurological Outcomes at University Hospitals Cleveland Medical Center (UHCMC) and directs the Neurological and Behavioral Outcomes Center at UHCMC/Case Western Reserve University. Behavioral Neurology and Neuropsychiatry is her subspecialty. Dr. Sajatovic teaches psychiatry and neurology at Case Western Reserve University School of Medicine (CWRU) in Cleveland, OH.
Professor Sajatovic has dedicated her career to the study and treatment of traditionally hard-to-treat populations with central nervous system disorders. Her research interests in neuropsychiatric outcomes of brain disorders across the life-span have included epilepsy, stroke, Alzheimer’s disease, vascular dementia, and Parkinson’s disease. Research interests of hers include self-management of chronic diseases like hypertension and diabetes, health disparities, and the use of health rating scales in clinical trials.
John Cacciola, Ph.D.
University of Pennsylvania School of Medicine
- Senior Scientist at the Treatment Research Institute (TRI)
- Adjunct Associate Professor of Psychology in Psychiatry
Dr. Cacciola is a leading substance abuse researcher with recognized expertise in diagnostic and psychosocial assessment, treatment outcomes, and co-occurring psychiatric disorders.
Dr. Cacciola has been extensively involved in the ongoing development of the Addiction Severity Index (ASI) and the Treatment Services Review (TSR).
He has co-authored more than 90 articles in scientific journals and was an advisor to the DSM-IV Substance Use Disorders Workgroup. Currently, a primary research area involves developing and testing innovative, efficient and adaptive approaches to substance abuse treatment.
Dawn Velligan, Ph.D.
University of Texas Health Science Center at San Antonio
- Professor in the Department of Psychiatry at the University of Texas Health Science Center
- Co-Chief of the Division of Schizophrenia and Related Disorders at the University of Texas Health Science Center
Dr. Velligan received her training in clinical psychology at the University of California and Mental Health Clinical Research Center for Schizophrenia in Los Angeles.
In 1989, Dr. Velligan moved to Texas to assist in the development of the University of Texas Health Science Center-San Antonio State Hospital Clinical Research Unit specializing in pharmaceutical and psychosocial studies of psychotic disorders.
Dr. Velligan’s internationally recognized research program focuses on the cognitive deficits associated with schizophrenia, the functional consequences of these deficits, and interventions to decrease cognitive impairment and improve community function in individuals with this illness.
Dr. Velligan is the author of numerous publications and is the principal investigator for various studies funded by the National Institute of Health, pharmaceutical companies, The National Alliance for Research on Schizophrenia and Depression, and private foundations.
Thomas R. Kosten, MD
Baylor College of Medicine
- Jay H. Waggoner Chair, Professor of Psychiatry and Neuroscience
- Director, Division of Alcohol and Addictive Disorders
- Mental Health Care Line Executive at Houston VA
In addition to his duties at Baylor, Dr. Kosten is research director of VA QUERI, the National Substance Use Disorders Quality Enhancement Research Initiative. Dr. Kosten has enjoyed an extraordinary career in substance abuse research and treatment in both the public and private sectors. Prior to assuming his current positions, Dr. Korsten was Professor at Yale University School of Medicine, and Chief of Psychiatry at VA Connecticut Healthcare System. Dr Kosten is founder of the Division of Substance Abuse at Baylor and Yale, directing their NIH Medications Development Center for substance abuse.
Dr. Kosten has been supported by a Research Scientist Award from the National Institutes of Health since 1987, and has served on national and international review groups for medications development in substance abuse. He has been a Congressional Fellow in the US House of Representatives and a visiting Professor in Germany, Spain, Greece, China, and Canada. Dr Kosten is the founding Vice Chair for Added Qualifications in Addiction Psychiatry of the American Board of Psychiatry and Neurology and a Distinguished Fellow in the American Psychiatric Association and Fellow of the American College of Neuropsychopharmacology.
Dr. Kosten is Past President of the American Academy of Addiction Psychiatry, and Past President of the College on Problems of Drug Dependence. Dr Kosten has also earned several major awards for clinical research, is editor of two major journals in substance abuse, and has been on the American Journal of Psychiatry board. His recent work includes serving on the National Academy of Sciences, Institute of Medicine committee on vaccines for substance abuse.
From his studies in substance dependence, post-traumatic stress disorder, and neuroimaging, Dr Kosten’s has published over 500 papers, books, and reviews. His neuroimaging research includes detecting and treating cocaine-induced cerebral perfusion defects, and using functional MRI to predict pharmacotherapy outcome. Dr Kosten’s medication contributions include vaccines for cocaine, opiates and methamphetamine, buprenorphine for opioid dependence, disulfiram for cocaine dependence, and combining medications with contingency management for opioid and cocaine dependence.
